Marinomed Biotech AG | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Marinomed Biotech AG

BRIEF

published on 06/30/2025 at 12:56, 5 months 4 days ago

Marinomed Biotech AG: Positive Outlook Amidst Strategic Turnaround

Marinomed Biotech AG Financial Restructuring Biotech Innovation Marinosolv® Platform Budesolv Development
PRESS RELEASE

published on 06/30/2025 at 12:51, 5 months 4 days ago

Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Marinomed Biotech AG with a Buy rating and EUR 50.00 price target. Details of the company's dual business model and lead candidate, Budesolv, are highlighted

First Berlin Equity Research BUY Rating Marinomed Biotech AG Biotech Company Dual Business Model
BRIEF

published on 06/06/2025 at 15:25, 5 months 28 days ago

Marinomed Biotech AG Partners to Launch Budesolv in Switzerland

International Expansion Marinomed Biotech AG Milestone Payments Pharma Partnership Budesolv Switzerland
PRESS RELEASE

published on 06/06/2025 at 15:20, 5 months 28 days ago

Marinomed Biotech AG announces partnership for Budesolv in Switzerland
Marinomed Biotech AG announces partnership with Swiss pharmaceutical company for the development and marketing of Budesolv in Switzerland, enabling milestone payments and royalties

Pharmaceutical Company Partnership Switzerland Marinomed Biotech AG Budesolv
BRIEF

published on 05/08/2025 at 09:25, 6 months 27 days ago

Marinomed Biotech AG Reports Strong Q1 2025 Financial Results

Financial Results Revenue Growth Marinomed Biotech AG First Quarter 2025 Restructuring Gain
PRESS RELEASE

published on 05/08/2025 at 09:20, 6 months 27 days ago

Marinomed Biotech AG announces results for the first quarter of 2025
Marinomed Biotech AG reports significant revenue growth and positive operating results in Q1 2025, despite ongoing cyber fraud investigations, maintaining strong liquidity position

Liquidity Revenue Growth Marinomed Biotech AG Operating Results Q1 2025
BRIEF

published on 04/10/2025 at 07:50, 7 months 24 days ago

Marinomed Biotech AG Launches New Eye Drops in Austria

Marinomed Biotech Medical Device Regulation Unither Pharmaceuticals Carragelose Eye Drops Austria Launch
PRESS RELEASE

published on 04/10/2025 at 07:45, 7 months 24 days ago

Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria
Marinomed Biotech AG launches new moisturizing Carragelose eye drops, 'Coldamaris protect', in Austria. Product complements existing portfolio, supports earn-out milestones, and meets new medical device regulation

Marinomed Biotech AG Carragelose Austria Medical Device Regulation Eye Drops
BRIEF

published on 03/27/2025 at 07:50, 8 months 8 days ago

Marinomed Targets Growth After Restructuring

Global Expansion Restructuring Marinomed Biotech Allergic Rhinitis Budesolv
PRESS RELEASE

published on 03/27/2025 at 07:45, 8 months 8 days ago

Marinomed focuses on growth after successful restructuring
Marinomed Biotech AG focuses on growth post-successful restructuring with innovative nasal corticosteroid Budesolv for allergic rhinitis treatment and global expansion plans

Global Expansion Restructuring Marinomed Biotech AG Allergic Rhinitis Budesolv

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 46 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 51 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 21 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 16 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 21 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 51 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 30 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 56 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 11 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 21 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 36 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 20 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE